Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Gestraud

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Genome Biology|October 24, 2025
Identification of microprotein-coding intronic polyadenylation isoforms and function in genotoxic anticancer drug responseAlexandre Devaux, Iris Tanaka, Quentin Fouilleul, et al.
Lung Cancer (Amsterdam, Netherlands)|May 24, 2022
Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcomeAlice Mogenet, Fabrice Barlesi, Benjamin Besse, et al.
Frontiers in Genetics|June 10, 2014
Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trialNicolas Servant, Julien Roméjon, Pierre Gestraud, et al.
British Journal of Cancer|August 1, 2024
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitorsMarie-Paule Sablin, Pierre Gestraud, Sarah Flora Jonas, et al.
NPJ Precision Oncology|July 18, 2024
Metastatic renal cell carcinoma with occult primary: a multicenter prospective cohortNicolas Jacquin, Ronan Flippot, Julien Masliah-Planchon, et al.
British Journal of Cancer|September 10, 2025
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosisAbderaouf Hamza, Pierre Gestraud, Maryam Karimi, et al.
Ebiomedicine|October 23, 2020
Genetic markers and phosphoprotein forms of beta-catenin pβ-Cat552 and pβ-Cat675 are prognostic biomarkers of cervical cancerSuzy M Scholl, Jonas Beal, Leanne de Koning, et al.
Molecular Oncology|August 5, 2020
Fine-needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next-generation sequencing in cancer patients included in the SHIVA02 trialCélia Dupain, Julien Masliah-Planchon, Céline Gu, et al.
EMBO Molecular Medicine|September 7, 2022
A catalog of numerical centrosome defects in epithelial ovarian cancersJean-Philippe Morretton, Anthony Simon, Aurélie Herbette, et al.
The Lancet Regional Health. Europe|November 24, 2025
Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysisCélia Dupain, Nicolas Jacquin, Aurélien Latouche, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Genome Biology|October 24, 2025
Identification of microprotein-coding intronic polyadenylation isoforms and function in genotoxic anticancer drug responseAlexandre Devaux, Iris Tanaka, Quentin Fouilleul, et al.
Lung Cancer (Amsterdam, Netherlands)|May 24, 2022
Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcomeAlice Mogenet, Fabrice Barlesi, Benjamin Besse, et al.
Frontiers in Genetics|June 10, 2014
Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trialNicolas Servant, Julien Roméjon, Pierre Gestraud, et al.
British Journal of Cancer|August 1, 2024
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitorsMarie-Paule Sablin, Pierre Gestraud, Sarah Flora Jonas, et al.
NPJ Precision Oncology|July 18, 2024
Metastatic renal cell carcinoma with occult primary: a multicenter prospective cohortNicolas Jacquin, Ronan Flippot, Julien Masliah-Planchon, et al.
British Journal of Cancer|September 10, 2025
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosisAbderaouf Hamza, Pierre Gestraud, Maryam Karimi, et al.
Ebiomedicine|October 23, 2020
Genetic markers and phosphoprotein forms of beta-catenin pβ-Cat552 and pβ-Cat675 are prognostic biomarkers of cervical cancerSuzy M Scholl, Jonas Beal, Leanne de Koning, et al.
Molecular Oncology|August 5, 2020
Fine-needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next-generation sequencing in cancer patients included in the SHIVA02 trialCélia Dupain, Julien Masliah-Planchon, Céline Gu, et al.
EMBO Molecular Medicine|September 7, 2022
A catalog of numerical centrosome defects in epithelial ovarian cancersJean-Philippe Morretton, Anthony Simon, Aurélie Herbette, et al.
The Lancet Regional Health. Europe|November 24, 2025
Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysisCélia Dupain, Nicolas Jacquin, Aurélien Latouche, et al.
Pageof 4